Cargando…

Australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (A*STEROID): study protocol

BACKGROUND: Both dexamethasone and betamethasone, given to women at risk of preterm birth, substantially improve short-term neonatal health, increase the chance of the baby being discharged home alive, and reduce childhood neurosensory disability, remaining safe into adulthood. However, it is unclea...

Descripción completa

Detalles Bibliográficos
Autores principales: Crowther, Caroline A, Harding, Jane E, Middleton, Philippa F, Andersen, Chad C, Ashwood, Pat, Robinson, Jeffrey S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655914/
https://www.ncbi.nlm.nih.gov/pubmed/23642125
http://dx.doi.org/10.1186/1471-2393-13-104
_version_ 1782269946878754816
author Crowther, Caroline A
Harding, Jane E
Middleton, Philippa F
Andersen, Chad C
Ashwood, Pat
Robinson, Jeffrey S
author_facet Crowther, Caroline A
Harding, Jane E
Middleton, Philippa F
Andersen, Chad C
Ashwood, Pat
Robinson, Jeffrey S
author_sort Crowther, Caroline A
collection PubMed
description BACKGROUND: Both dexamethasone and betamethasone, given to women at risk of preterm birth, substantially improve short-term neonatal health, increase the chance of the baby being discharged home alive, and reduce childhood neurosensory disability, remaining safe into adulthood. However, it is unclear which corticosteroid is of greater benefit to mother and child. This study aims to determine whether giving dexamethasone to women at risk of preterm birth at less than 34 weeks’ gestation increases the chance of their children surviving free of neurosensory disability at two years’ corrected age, compared with betamethasone. METHODS/DESIGN: Design randomised, multicentre, placebo controlled trial. Inclusion criteria women at risk of preterm birth at less than 34 weeks’ gestation with a singleton or twin pregnancy and no contraindications to the use of antenatal corticosteroids and who give informed consent. Trial entry & randomisation at telephone randomisation eligible women will be randomly allocated to either the dexamethasone group or the betamethasone group, allocated a study number and corresponding treatment pack. Study groups women in the dexamethasone group will be administered two syringes of 12 mg dexamethasone (dexamethasone sodium phosphate) and women in the betamethasone group will be administered two syringes of 11.4 mg betamethasone (Celestone Chronodose). Both study groups consist of intramuscular treatments 24 hours apart. Primary study outcome death or any neurosensory disability measured in children at two years’ corrected age. Sample size a sample size of 1449 children is required to detect either a decrease in death or any neurosensory disability from 27.0% to 20.1% with dexamethasone compared with betamethasone, or an increase from 27.0% to 34.5% (two-sided alpha 0.05, 80% power, 5% loss to follow up, design effect 1.2). DISCUSSION: This study will provide high-level evidence of direct relevance for clinical practice. If one drug clearly results in significantly fewer deaths and fewer disabled children then it should be used consistently in women at risk of preterm birth and would be of great importance to women at risk of preterm birth, their children, health services and communities. TRIAL REGISTRATION: Trial registration number: ACTRN12608000631303
format Online
Article
Text
id pubmed-3655914
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36559142013-05-17 Australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (A*STEROID): study protocol Crowther, Caroline A Harding, Jane E Middleton, Philippa F Andersen, Chad C Ashwood, Pat Robinson, Jeffrey S BMC Pregnancy Childbirth Study Protocol BACKGROUND: Both dexamethasone and betamethasone, given to women at risk of preterm birth, substantially improve short-term neonatal health, increase the chance of the baby being discharged home alive, and reduce childhood neurosensory disability, remaining safe into adulthood. However, it is unclear which corticosteroid is of greater benefit to mother and child. This study aims to determine whether giving dexamethasone to women at risk of preterm birth at less than 34 weeks’ gestation increases the chance of their children surviving free of neurosensory disability at two years’ corrected age, compared with betamethasone. METHODS/DESIGN: Design randomised, multicentre, placebo controlled trial. Inclusion criteria women at risk of preterm birth at less than 34 weeks’ gestation with a singleton or twin pregnancy and no contraindications to the use of antenatal corticosteroids and who give informed consent. Trial entry & randomisation at telephone randomisation eligible women will be randomly allocated to either the dexamethasone group or the betamethasone group, allocated a study number and corresponding treatment pack. Study groups women in the dexamethasone group will be administered two syringes of 12 mg dexamethasone (dexamethasone sodium phosphate) and women in the betamethasone group will be administered two syringes of 11.4 mg betamethasone (Celestone Chronodose). Both study groups consist of intramuscular treatments 24 hours apart. Primary study outcome death or any neurosensory disability measured in children at two years’ corrected age. Sample size a sample size of 1449 children is required to detect either a decrease in death or any neurosensory disability from 27.0% to 20.1% with dexamethasone compared with betamethasone, or an increase from 27.0% to 34.5% (two-sided alpha 0.05, 80% power, 5% loss to follow up, design effect 1.2). DISCUSSION: This study will provide high-level evidence of direct relevance for clinical practice. If one drug clearly results in significantly fewer deaths and fewer disabled children then it should be used consistently in women at risk of preterm birth and would be of great importance to women at risk of preterm birth, their children, health services and communities. TRIAL REGISTRATION: Trial registration number: ACTRN12608000631303 BioMed Central 2013-05-03 /pmc/articles/PMC3655914/ /pubmed/23642125 http://dx.doi.org/10.1186/1471-2393-13-104 Text en Copyright © 2013 Crowther et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Crowther, Caroline A
Harding, Jane E
Middleton, Philippa F
Andersen, Chad C
Ashwood, Pat
Robinson, Jeffrey S
Australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (A*STEROID): study protocol
title Australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (A*STEROID): study protocol
title_full Australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (A*STEROID): study protocol
title_fullStr Australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (A*STEROID): study protocol
title_full_unstemmed Australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (A*STEROID): study protocol
title_short Australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (A*STEROID): study protocol
title_sort australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (a*steroid): study protocol
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655914/
https://www.ncbi.nlm.nih.gov/pubmed/23642125
http://dx.doi.org/10.1186/1471-2393-13-104
work_keys_str_mv AT crowthercarolinea australasianrandomisedtrialtoevaluatetheroleofmaternalintramusculardexamethasoneversusbetamethasonepriortopretermbirthtoincreasesurvivalfreeofchildhoodneurosensorydisabilityasteroidstudyprotocol
AT hardingjanee australasianrandomisedtrialtoevaluatetheroleofmaternalintramusculardexamethasoneversusbetamethasonepriortopretermbirthtoincreasesurvivalfreeofchildhoodneurosensorydisabilityasteroidstudyprotocol
AT middletonphilippaf australasianrandomisedtrialtoevaluatetheroleofmaternalintramusculardexamethasoneversusbetamethasonepriortopretermbirthtoincreasesurvivalfreeofchildhoodneurosensorydisabilityasteroidstudyprotocol
AT andersenchadc australasianrandomisedtrialtoevaluatetheroleofmaternalintramusculardexamethasoneversusbetamethasonepriortopretermbirthtoincreasesurvivalfreeofchildhoodneurosensorydisabilityasteroidstudyprotocol
AT ashwoodpat australasianrandomisedtrialtoevaluatetheroleofmaternalintramusculardexamethasoneversusbetamethasonepriortopretermbirthtoincreasesurvivalfreeofchildhoodneurosensorydisabilityasteroidstudyprotocol
AT robinsonjeffreys australasianrandomisedtrialtoevaluatetheroleofmaternalintramusculardexamethasoneversusbetamethasonepriortopretermbirthtoincreasesurvivalfreeofchildhoodneurosensorydisabilityasteroidstudyprotocol